Rapt Therapeutics (NASDAQ:RAPT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Rapt Therapeutics (NASDAQ:RAPT) to a hold rating in a report released on Saturday.

A number of other equities analysts have also recently weighed in on the stock. HC Wainwright cut shares of Rapt Therapeutics from a “buy” rating to a “neutral” rating and set a $58.00 price objective for the company. in a research report on Tuesday, January 20th. TD Cowen lowered shares of Rapt Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Lifesci Capital cut shares of Rapt Therapeutics from an “outperform” rating to a “hold” rating in a research note on Tuesday, January 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Rapt Therapeutics in a research report on Thursday, January 22nd. Finally, Clear Str lowered shares of Rapt Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $48.44.

Rapt Therapeutics Price Performance

Shares of RAPT stock opened at $58.02 on Friday. Rapt Therapeutics has a 1-year low of $5.67 and a 1-year high of $58.02. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -5.25 and a beta of 0.49. The stock has a 50 day simple moving average of $50.39 and a 200-day simple moving average of $35.01.

Institutional Trading of Rapt Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in RAPT. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Rapt Therapeutics during the fourth quarter worth $46,000. China Universal Asset Management Co. Ltd. purchased a new stake in Rapt Therapeutics in the fourth quarter valued at $153,000. Bank of Nova Scotia acquired a new position in shares of Rapt Therapeutics in the 4th quarter valued at $227,000. Voloridge Investment Management LLC acquired a new position in shares of Rapt Therapeutics in the 4th quarter valued at $233,000. Finally, Virtus Investment Advisers LLC purchased a new position in shares of Rapt Therapeutics during the 4th quarter worth $245,000. Institutional investors and hedge funds own 99.09% of the company’s stock.

About Rapt Therapeutics

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.